-+ 0.00%
-+ 0.00%
-+ 0.00%

NeuroSense Therapeutics Announces Its Phase 2B PARADIGM Study Of PrimeC In Amyotrophic Lateral Sclerosis Has Met Its Primary Efficacy Endpoint

Benzinga·06/29/2026 13:32:22
Listen to the news
  • First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS
  • TDP-43 pathology is present in more than 97% of ALS cases and is widely recognized as a central driver of disease progression
  • PrimeC demonstrates target engagement with consistent effects across clinical outcomes, survival, and biomarkers, supporting its potential as a disease-modifying therapy